Abstract: Disclosed is a method of producing 5?-guanosine monophosphate using a novel microorganism which has a malate dehydrogenase activity higher than that of a wild-type, thereby showing improved ATP productivity. Also, a novel microorganism is disclosed. The method comprises: culturing the corynebacteria strain which is enhanced in malate dehydrogenase activity over the endogenous activity, thus producing ATP in high yield; producing XMP in the culture; adding to the culture an enzyme or microorganism having XMP amination activity; and obtaining GMP from the culture.

Abstract: The present invention relates to a microorganism with improved production of 5?-xanthosine monophosphate and 5?-guanine monophosphate, and more specifically, to a Corynebacterium sp. microorganism having increased proline dehydrogenase activity compared with an intrinsic activity thereof, a method for producing 5?-xanthosine monophosphate or 5?-guanine monophosphate from the culture medium obtained by culturing the transformed microorganism, and a use of the microorganism for production of 5?-xanthosine monophosphate or 5?-guanine monophosphate.

Abstract: Disclosed herein is a method and system for measuring magnetoelectric susceptibility. The system includes a magnet supplying a DC magnetic bias to a magnetoelectric sample, an AC drive coil applying an AC magnetic field to the magnetoelectric sample, a charge amplifier amplifying an electric charge signal of the magnetoelectric sample oscillating by the AC magnetic field, and a phase sensitive detector detecting the voltage signal produced by the charge amplifier while supplying induction current to the AC drive coil. Accordingly, it is possible to provide a highly sensitive system for measuring magnetoelectric susceptibility, which is essential for research on multiferroic and magnetoelectric bulk and thin film materials at room temperature, and can also operate in the physical property measurement system (PPMS, manufactured by Quantum Design Co., Ltd.) for measurements under low temperature and high magnetic field environments.

Abstract: Disclosed is a novel microorganism which has a malate dehydrogenase activity higher than that of a wild-type. Also, a recombinant vector which has the structure shown in the cleavage map of FIG. 1, a Corynebacteria strain transformed therewith, and a method of producing 5?-xanthosine monophosphate by culturing the transformed strain are disclosed.

Abstract: Disclosed is a method of producing 5?-guanosine monophosphate using a novel microorganism which has a malate dehydrogenase activity higher than that of a wild-type, thereby showing improved ATP productivity. Also, a novel microorganism is disclosed. The method comprises: culturing the corynebacteria strain which is enhanced in malate dehydrogenase activity over the endogenous activity, thus producing ATP in high yield; producing XMP in the culture; adding to the culture an enzyme or microorganism having XMP amination activity; and obtaining GMP from the culture.

Abstract: The present invention relates to a novel imatinib camsylate and a method for preparing the same. Imatinib camsylate according to the present invention has a faster absorption rate and higher absorption concentration in terms of pharmacokinetics, and further has excellent water solubility, as compared to commercially available imatinib mesylate.

Abstract: Disclosed herein is a method and system for measuring magnetoelectric susceptibility. The system includes a magnet supplying a DC magnetic bias to a magnetoelectric sample, an AC drive coil applying an AC magnetic field to the magnetoelectric sample, a charge amplifier amplifying an electric charge signal of the magnetoelectric sample oscillating by the AC magnetic field, and a phase sensitive detector detecting the voltage signal produced by the charge amplifier while supplying induction current to the AC drive coil. Accordingly, it is possible to provide a highly sensitive system for measuring magnetoelectric susceptibility, which is essential for research on multiferroic and magnetoelectric bulk and thin film materials at room temperature, and can also operate in the physical property measurement system (PPMS, manufactured by Quantum Design Co., Ltd.) for measurements under low temperature and high magnetic field environments.

Abstract: The present invention relates to quinolonecarboxylic acid derivatives having more excellent and broad antibacterial activities than the existing quinolone-series antibiotic. More specifically, it pertains to novel quinolonecarboxylic acid derivative represented by following formula 1, which have a derivative of 7-[8-(alkoxyimino)-2,6-diazaspiro[3.4]oct-6-yl] as a substituent, and pharmaceutically acceptable salts and isomers thereof: Wherein A is C—H, C—F, C—Cl, C—O—CH3 or N; Y is H or amino; R1 is cyclopropyl or 2,4-difluorsophenyl R2 is C1-4 alkyl; and R3 is H or C1-4 alkyl.

Abstract: The present invention relates to quinolonecarboxylic acid derivatives having more excellent and broad antibacterial activities than the existing quinolone-series antibiotic. More specifically, it pertains to novel quinolonecarboxyllic acid derivative represented by following formula 1, which have a derivative of 7-[8-(alkoxyimino)-2,6-diazaspiro[3.

Abstract: The present invention relates to quinolonecarboxylic acid derivatives having more excellent and broad antibacterial activities than the existing quinolone-series antibiotics. More specifically, it pertains to novel quinolonecarboxylic acid derivatives represented by following formula 1, which have a derivative of 7-[8-(alkoxyimino)-2,6-diazaspiro[3.4]oct-6-yl] as a substituent, and pharmaceutically acceptable salts and isomers thereof: Wherein, A is C—H, C—F, C—Cl, C—O—CH3 or N; Y is H or amino; R1 is cyclopropyl or 2,4-difluorophenyl; R2 is C1-4 alkyl; and R3 is H or C1-4 alkyl.

Abstract: The Centralized Management System utilizing a Bus Interface Unit comprises a Computer (4z) installing an address Bus (4a), data Bus (4b), and control Bus (4c), a First-Level Station (4Q1) communicating with the Computer (4z) as the First-Level Station (4Q1) is connected to the buses (4a, 4b, 4c) of the Computer (4z), a plurality of second-level stations (4Q2, 4Q3, . . . , 4QM) communicating with the First-Level Station (4Q1) as the second-level stations (4Q2, 4Q3, . . . , 4QM) are connected to the First-Level Station through a Multipoint Bus (4r). Therefore, the Centralized Management System is capable of communicating the Computer with the First-Level Station through a Dual Port RAM (Random Access Memory), intercommunicating a plurality of Second-Level Stations through a Multipoint Interface and Multipoint Bus, and controlling and managing several thousands of Terminals (for example, Public Telephones).

Abstract: The present invention relates to the novel quinolone carboxylic acid derivatives of the following formula (I) and their pharmaceutically acceptable salts and their hydrates. ##STR1## wherein X is a hydrocarbon, fluorocarbon or nitrogen atom,Y is a hydrogen or methyl group,R.sup.1 is a hydrogen or alkyl group having 1 to 5 carbon atom,R.sup.2 is ##STR2## wherein A and B is a fluorocarbon or nitrogen atom, provided that, if A.dbd.CF, B.dbd.N and if A.dbd.N, B.dbd.CF) andR.sup.3 is ##STR3## (wherein R.sup.4 is an amino group which makes a racemate or (S)-enantiomer) or ##STR4## (wherein R.sup.5, R.sup.6 and R.sup.7 are respectively hydrogen or alkyl group having 1 to 3 carbon atom.).The compounds according to the present invention are used as antibacterial agents.